Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that patients with androgenetic alopecia had a higher incidence of metabolic syndrome and benign prostatic hyperplasia compared to those without the condition.

In this study, researchers found that the microRNA miR-1199-5p may reduce the expression of SRD5A2 in benign prostatic hyperplasia tissues, potentially contributing to the failure of 5-α reductase inhibitor therapy in some patients.

Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.

This review discusses sexual dysfunction as a potential side effect of drugs for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms and reports no new clinical results; it emphasizes the need for methodologically robust studies.

This study suggests that using both finasteride and dutasteride may increase the risk of acute coronary syndrome in patients with benign prostate hyperplasia.

This study found that the petroleum ether extract of Citrullus colocynthis fruit and an isolated steroidal compound may reduce prostatic hyperplasia in rats induced by testosterone, suggesting potential use in managing androgen-dependent conditions.

This study found that treating dogs with benign prostatic hyperplasia using osaterone acetate reduced prostatic volume and increased diffusion times of an ultrasound contrast agent, suggesting effective treatment and potential for CEUS monitoring.

In this study, the authors observed that treatment patterns for new benign prostatic hyperplasia largely aligned with guidelines, but 5-α reductase inhibitors were used inappropriately based on prostate size as indicated by prostate specific antigen.

This study found that keratinocyte growth factor is a potent mitogen in human hyperplastic prostate cells, suggesting it plays an important role in prostate growth by acting in a paracrine manner.

This study found that LHE may prevent and reverse testosterone-induced prostatic hyperplasia, supporting the traditional use of Kigelia africana for some reproductive system disorders.

This study found that Medicare patients with benign prostatic hyperplasia had high adherence to 5-alpha reductase inhibitor therapy, which was associated with a reduced risk of needing surgical intervention.

The abstract discusses that Serenoa repens, a commonly used phytotherapeutic agent, may play a crucial role as an alternative or complementary treatment for lower urinary tract symptoms in patients with benign prostatic hyperplasia, particularly those with mild-to-moderate disease severity.

In this study conducted at Sir Ganga Ram Teaching Hospital in Pakistan, researchers found that preoperative use of finasteride significantly reduced intraoperative blood loss and shortened hospital stay for benign prostatic hyperplasia patients undergoing bipolar TURP, compared to those not receiving finasteride.

In a rat model of benign prostatic hyperplasia, this study found that purple corn extract may improve symptoms by inhibiting prostate enlargement, reducing androgen receptor signaling, and exerting anti-inflammatory effects.

This cohort study using real-world data found no significant difference in the risk of developing prostate cancer between finasteride and dutasteride among patients with benign prostatic hyperplasia, despite previous suggestions that dutasteride might be more effective.

This study found that high-dose pterostilbene potentially reduced prostate hyperplasia and had strong antioxidant effects in male rats with benign prostatic hyperplasia, suggesting it might be more effective than vitamin C and resveratrol in similar contexts.

Using finasteride for hair loss or prostate issues does not significantly raise the risk of erectile dysfunction.

This study found that Zhuangyao Jianshen pill significantly improved prostate health in testosterone-induced benign prostatic hyperplasia in castrated rats by modulating sex hormones and reducing inflammation and oxidative stress.

Among a Han Chinese cohort, this study found that a higher genetic risk score was linked to increased susceptibility to BPH, larger prostate size, reduced effectiveness of 5ARI treatment, and a higher risk of undergoing TURP.

This literature review identified that phosphodiesterase 5 inhibitors, such as Tadalafil, are highly effective in improving lower urinary tract symptoms associated with benign prostatic hyperplasia, while the efficacy of saw palmetto remains inconsistent.

This cohort study found no overall increased risk of suicidal behaviors with finasteride versus dutasteride in men aged 50 and older, but suggested potential risk for those with a history of mood disorders.

In this study, the use of 5-α reductase inhibitors was not associated with an increased risk of anaemia compared to α-blockers in men with benign prostatic hyperplasia.

Corni Fructus extract may help manage benign prostatic hyperplasia by reducing prostate cell growth and inflammation.

This study reported that ginseng had a superior therapeutic effect on benign prostatic hyperplasia in rats, showing nearly normal histological architecture compared to finasteride's incomplete restoration.

This study found that Croton membranaceus root extract induced CYP1A2 and GSTM1 enzymes but inhibited CYP3A4 and CYP2D6 in rat livers, suggesting caution in its use with other drugs.

This study found a positive association between erectile dysfunction and the functionality of the marital subsystem in patients with benign prostatic hyperplasia treated with tamsulosin and finasteride.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

In this study, androgenetic alopecia patients with thin hair were found to have a higher likelihood of experiencing prostatic enlargement and related urinary symptoms compared to those with thicker hair.

This case report documents a 59-year-old man in Taiwan who developed breast cancer while undergoing finasteride therapy for benign prostate hyperplasia, marking a rare side effect.

This study found that finasteride at a low dose of 0.1 mg/kg significantly reduced prostate size in male dogs with benign prostatic hyperplasia without causing toxic side effects.